Browsing Tag
EYLEA HD
3 posts
EyePoint reaches full DME enrollment with $222.5m and a runway ending near the readout
EyePoint completes Phase 3 DME enrollment as DURAVYU targets six-month dosing, with wet AMD data due in August and DME results in late 2027.
Why Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) just strengthened the Eylea HD case against Roche’s Vabysmo
Regeneron won FDA approval for every-20-week Eylea HD dosing in wet AMD and DME. Read what it means for Regeneron, rivals, and retinal drug markets.
EYLEA HD and DUPIXENT anchor Regeneron’s 2026 growth plan amid clinical pipeline acceleration
Find out how Regeneron’s 18 new Phase III trials and four FDA approval targets in 2026 aim to reshape growth beyond DUPIXENT and EYLEA. Read the full story.